| 08:30 | 1907 | Long-term follow-up of the patients with Aspirin resistant end stage kidney disease | C Kocas (Istanbul, TR) |
|
|
Abstract
|
|
|
|
Slides
|
|
|
| 08:45 | 1908 | Good short-term but not long-term reproducibility of the antiplatelet efficacy laboratory assessment | J F Vojacek (Prague 4, CZ) |
|
|
|
Abstract
|
|
|
|
|
Slides
|
|
|
| 09:00 | 1909 | Prevention of peptic ulcers with once-daily esomeprazole 20 mg and 40 mg in low-dose acetylsalicylic acid users at gastrointestinal risk: outcome analysis by cardiovascular risk (OBERON) | J Scheiman (Ann Arbor, US) |
|
|
|
Abstract
|
|
|
|
|
Slides
|
|
|
| 09:15 | 1910 | Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes mellitus and renal impairment - the FIELD study | R Ting (Balmain, AU) |
|
|
|
Abstract
|
|
|
| 09:30 | 1911 | Long-term effects of angiotensin II receptor blockers in hypertensive patients with chronic kidney disease and the metabolic syndrome | H Watanabe (Joso, JP) |
|
|
|
Abstract
|
|
|
|
|
Slides
|
|
|
| 09:45 | 1912 | Effective management of glycosylated hemoglobin levels with niacin extended release among patients with type II diabetes mellitus | R Simko (Chicago, US) |
|
|
|
Abstract
|
|
|